NDA 217424 · Lnhc
Zelsuvmi
Berdazimer Sodium · Topical
NovelCDER novel approval, Jan 5, 2024: To treat molluscum contagiosum
Last checked: Nov 19, 2026Latest source record: Jan 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jan 5, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
20
6 Phase 3, 0 recruiting
FAERS reports
95
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 8, 2025.
ZELSUVMI™ is indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older. ZELSUVMI™ is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older. ( 1 )
Mechanism: ZELSUVMI is a nitric oxide releasing agent. The mechanism of action for the treatment of molluscum contagiosum is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ZELSUVMI · BERDAZIMER SODIUM EQ 10.3% BASE · GEL, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Berdazimer" as an intervention, any sponsor and status, largest first.
- P3 Study Comparing Once Daily SB204 and Vehicle Gel in AcnePivotal-lookingCompleted
Novan, Inc.Industry
NCT02667444 · 1,330 participants · Start Feb 19, 2016 · Primary completion Dec 2016
Drug: SB204 4%; Vehicle Gel · For: Acne Vulgaris
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 55 sites in all
- P3 Study in Acne Comparing Once Daily SB204 and VehiclePivotal-lookingCompleted
Novan, Inc.Industry
NCT02672332 · 1,307 participants · Start Feb 22, 2016 · Primary completion Dec 2016
Drug: SB204 4%; Vehicle Gel · For: Acne Vulgaris
Sites: Anaheim, California; Encinitas, California; Fresno, California · 55 sites in all
- A Phase 3 Molluscum Contagiosum Efficacy and Safety StudyPivotal-lookingCompleted
Novan, Inc.Industry
NCT04535531 · 891 participants · Start Sep 1, 2020 · Primary completion Apr 28, 2021
Drug: SB206 10.3% berdazimer; vehicle gel · For: Molluscum Contagiosum
Sites: Glendale, Arizona; Hot Springs, Arkansas; Rogers, Arkansas · 55 sites in all
- P3 Long Term Safety Study of Once Daily SB204 in AcnePivotal-lookingCompleted
Novan, Inc.Industry
NCT02798120 · 601 participants · Start May 12, 2016 · Primary completion Apr 2017
Drug: SB204 4% · For: Acne Vulgaris
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 69 sites in all
- A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MCPivotal-lookingCompleted
Novan, Inc.Industry
NCT03927703 · 355 participants · Start Jun 13, 2019 · Primary completion Nov 11, 2019
Drug: SB206 12%; Placebo · For: Molluscum Contagiosum
Sites: Scottsdale, Arizona; Hot Springs, Arkansas; Beverly Hills, California · 27 sites in all
- A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)Pivotal-lookingCompleted
Novan, Inc.Industry
NCT03927716 · 352 participants · Start Jun 3, 2019 · Primary completion Oct 28, 2019
Drug: SB206 12%; Placebo · For: Molluscum Contagiosum
Sites: Mobile, Alabama; Glendale, Arizona; Little Rock, Arkansas · 35 sites in all
- A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum ContagiosumPivotal-lookingCompleted
Novan, Inc.Industry
NCT03436615 · 256 participants · Start Jan 24, 2018 · Primary completion Nov 3, 2018
Drug: SB206 4%; SB206 8% and 2 more · For: Molluscum Contagiosum
Sites: Scottsdale, Arizona; Santa Ana, California; Thornton, Colorado · 18 sites in all
- P2 Multi-center Study of SB204 Gel in the Treatment of Acne VulgarisPivotal-lookingCompleted
Novan, Inc.Industry
NCT02242760 · 213 participants · Start Nov 2014 · Primary completion Jun 2015
Drug: SB204 2%; SB204 4% and 1 more · For: Acne Vulgaris
Sites: Hot Springs, Arkansas; Encinitas, California; San Diego, California · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- application site pain46
- application site erythema31
- application site pruritus12
- application site vesicles9
- application site discolouration8
- application site irritation8
- application site rash8
- application site exfoliation6
- wrong technique in product usage process6
- application site inflammation5
- application site eczema4
- application site scab4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 19 |
| 2026 | 76 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatments for molluscum contagiosum: A systematic review.
Wang OJE, Shergill M, Saed Aldien A, et al. · J Dtsch Dermatol Ges 2026 · Systematic Review
- Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis.
Paller AS, Green LJ, Silverberg N, et al. · Pediatr Dermatol 2024 · Randomized Controlled Trial, Multicenter Study
- Safety and efficacy of topical nitric oxide-releasing berdazimer gel for molluscum contagiosum clearance: A systematic review and meta-analysis of randomized controlled trials.
Pera Calvi I, R Marques I, Cruz SA, et al. · Pediatr Dermatol 2023 · Systematic Review, Meta-Analysis
- Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial.
Browning JC, Enloe C, Cartwright M, et al. · JAMA Dermatol 2022 · Clinical Trial, Phase III, Multicenter Study
- A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results.
Browning JC, Cartwright M, Thorla I, et al. · Am J Clin Dermatol 2023 · Randomized Controlled Trial
- A Phase 2 Controlled Study of SB206, a Topical Nitric Oxide-Releasing Drug for Extragenital Wart Treatment.
Tyring SK, Rosen T, Berman B, et al. · J Drugs Dermatol 2018 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Lnhc
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.